Aquestive Therapeutics Inc (AQST) — Cash Flow-to-Debt Ratio
Aquestive Therapeutics Inc (AQST) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-14.81 Million could theoretically repay 0% of its total liabilities ($175.18 Million) in one year. See Aquestive Therapeutics Inc (AQST) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aquestive Therapeutics Inc Cash Flow-to-Debt Ratio (2005–2025)
Historical debt coverage capacity for Aquestive Therapeutics Inc across 12 annual periods. For the full cash flow conversion analysis, see AQST cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Aquestive Therapeutics Inc (2005–2025)
Year-by-year debt coverage analysis for Aquestive Therapeutics Inc. Check Aquestive Therapeutics Inc (AQST) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.27x | $-52.43 Million | $194.09 Million | ▼ -22.1% |
| 2024 | -0.22x | $-35.76 Million | $161.58 Million | ▼ -468.6% |
| 2023 | -0.04x | $-6.38 Million | $163.91 Million | ▲ +30.2% |
| 2022 | -0.06x | $-9.79 Million | $175.62 Million | ▲ +75.6% |
| 2021 | -0.23x | $-32.98 Million | $144.13 Million | ▲ +43.9% |
| 2020 | -0.41x | $-45.46 Million | $111.38 Million | ▲ +42.7% |
| 2019 | -0.71x | $-60.21 Million | $84.60 Million | ▼ -320.6% |
| 2018 | -0.17x | $-12.99 Million | $76.77 Million | ▼ -302.3% |
| 2017 | 0.08x | $5.82 Million | $69.61 Million | ▲ +158.3% |
| 2016 | -0.14x | $-8.18 Million | $56.97 Million | ▲ +97.0% |
| 2006 | -4.83x | $-9.26 Million | $1.92 Million | ▼ -477.2% |
| 2005 | -0.84x | $-6.39 Million | $7.64 Million | — |